Application From the Joint Commission (TJC) for Continued Approval of its Psychiatric Hospital Accreditation Program, 12363-12365 [2023-03925]
Download as PDF
12363
Federal Register / Vol. 88, No. 38 / Monday, February 27, 2023 / Notices
infections, including monkeypox, in
adults and children of all ages.
FDA regulations require that an
Institutional Review Board (IRB) review,
approve and maintain oversight of the
activities under the EA–IND as set forth
in 21 CFR parts 50, 56, and 312. The
CDC IRB is positioned to serve as the
central IRB for review and approval of
the EA–IND consistent 21 CFR 56.114.
This arrangement allows facilities to use
or rely on the CDC IRB for centralized
review and approval for this protocol in
place of review by the site-specific IRB
to help reduce duplication of effort,
delays, and increased expenses. Any
facility that receives tecovirimat for
treatment of orthopoxvirus infection
under the EA–IND may elect to rely on
the CDC IRB to meet FDA’s regulatory
requirements.
The IRB review is required by FDA
under the CDC’s approved EA–IND.
Therefore, CDC must maintain records
of which facilities have elected to rely
on the CDC IRB for centralized review
and which facilities elect to obtain IRB
review on their own. CDC will use
collected data to track and document
the institutions relying on the CDC IRB
so they can provide TPOXX treatment to
their patients with monkeypox under
the EA–IND.
This collection was initially approved
as an Emergency ICR in August 2022
(OMB Control No. 0920–1366), and is
being submitted here to create a
standard version of the collection. CDC
requests OMB approval for an estimated
1,333 annual burden hours. There is no
cost to respondents other than their time
to participate.
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
Hospital/IRB Administrators ............................
CDC IRB Authorization Agreement (for review).
CDC IRB Authorization Agreement (for completion and submission to CDC).
Hospital/IRB Administrators ............................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2023–03961 Filed 2–24–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3430–FN]
Application From the Joint
Commission (TJC) for Continued
Approval of its Psychiatric Hospital
Accreditation Program
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
This notice announces our
decision to approve the Joint
Commission for continued recognition
as a national accrediting organization
for psychiatric hospitals that wish to
participate in the Medicare or Medicaid
programs.
DATES: This notice is effective February
25, 2023 through February 25, 2029.
FOR FURTHER INFORMATION CONTACT:
Danielle Adams (410) 786–8818, Donald
Howard (410) 786–6764 or Lillian
Williams (410) 786–8636.
SUPPLEMENTARY INFORMATION:
SUMMARY:
ddrumheller on DSK120RN23PROD with NOTICES
Number of
respondents
Type of respondent
I. Background
Under the Medicare program, eligible
beneficiaries may receive covered
services from a psychiatric hospital
VerDate Sep<11>2014
20:06 Feb 24, 2023
Jkt 259001
provided certain requirements are met.
Section 1861(f) of the Social Security
Act (the Act) establishes distinct criteria
for facilities seeking designation as a
psychiatric hospital. Regulations
concerning provider agreements are at
42 CFR part 489 and those pertaining to
activities relating to the survey and
certification of facilities are at 42 CFR
part 488. The regulations at 42 CFR part
482, subpart E, specify the minimum
conditions that a psychiatric hospital
must meet to participate in the Medicare
program, the scope of covered services,
and the conditions for Medicare
payment for psychiatric hospitals.
Generally, to enter into a provider
agreement, a psychiatric hospital must
first be certified by a State Survey
Agency as complying with the
conditions or requirements set forth in
part 482 subpart E of our regulations.
Thereafter, the psychiatric hospital is
subject to regular surveys by a State
Survey Agency to determine whether it
continues to meet these requirements.
Section 1865(a)(1) of the Act provides
that, if a provider entity demonstrates
through accreditation by an approved
national accrediting organization (AO)
that all applicable Medicare conditions
are met or exceeded, we may treat the
provider entity as having met those
conditions; that is, we may ‘‘deem’’ the
provider entity as having met the
requirements. Accreditation by an AO is
voluntary and is not required for
Medicare participation.
If an AO is recognized by the
Secretary of the Department of Health
and Human Services (the Secretary) as
having standards for accreditation that
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
Number
responses per
respondent
Avg. burden
per response
(in hours)
500
1
1
500
10
10/60
meet or exceed Medicare requirements,
any provider entity accredited by the
national accrediting body’s approved
program may be deemed to meet the
Medicare conditions. A national AO
applying for approval of its
accreditation program under part 488,
subpart A, must provide Centers for
Medicare & Medicaid Services (CMS)
with reasonable assurance that the AO
requires the accredited provider entities
to meet requirements that are at least as
stringent as the Medicare conditions.
Our regulations concerning the approval
of AO are set forth at § 488.5. The
regulations at § 488.5(e)(2)(i) require AO
to reapply for continued approval of its
accreditation program every 6 years or
sooner as determined by CMS.
The Joint Commission’s current term
of approval for their psychiatric hospital
accreditation program expires February
25, 2023.
II. Application Approval Process
Section 1865(a)(3)(A) of the Act
provides a statutory timetable to ensure
that our review of applications for CMS
approval of an accreditation program is
conducted in a timely manner. The Act
provides no more than 210 days after
the date of receipt of a complete
application, including any
documentation necessary to make the
determination, for CMS to complete its
application review process. Within 60
days after receiving a complete
application, we must publish a notice in
the Federal Register that identifies the
national accrediting body making the
request, describes the request, and
provides no less than a 30-day public
E:\FR\FM\27FEN1.SGM
27FEN1
12364
Federal Register / Vol. 88, No. 38 / Monday, February 27, 2023 / Notices
ddrumheller on DSK120RN23PROD with NOTICES
comment period. At the end of the 210day period, we must publish a notice in
the Federal Register approving or
denying the application.
III. Provisions of the Proposed Notice
In the September 30, 2022 Federal
Register (87 FR 59435), we published a
proposed notice announcing The Joint
Commission (TJC) request for continued
approval of its Medicare psychiatric
hospital accreditation program. In the
September 30, 2022 notice, we detailed
our evaluation criteria. Under the
authority of Section 1865(a)(2) of the
Act and our regulations at § 488.5, we
conducted a review of TJC’s Medicare
psychiatric hospital accreditation
renewal application in accordance with
the criteria specified by our regulations,
which include, but are not limited to,
the following:
• An onsite administrative review of
TJC’s: (1) Corporate policies; (2)
financial and human resources available
to accomplish the proposed surveys; (3)
procedures for training, monitoring, and
evaluation of its psychiatric hospital
surveyors; (4) ability to investigate and
respond appropriately to complaints
against accredited psychiatric hospitals;
and (5) survey review and decisionmaking process for accreditation.
• The comparison of TJC’s Medicare
psychiatric hospital accreditation
program standards to our current
Medicare hospitals Conditions of
Participation (CoPs) and psychiatric
hospital special conditions.
• A documentation review of TJC’s
psychiatric hospital survey process to:
++ Determine the composition of the
survey team, surveyor qualifications,
and TJC’s ability to provide continuing
surveyor training.
++ Compare TJC’s processes to those
we require of state survey agencies,
including periodic resurvey and the
ability to investigate and respond
appropriately to complaints against
accredited psychiatric hospitals.
++ Evaluate TJC’s procedures for
monitoring psychiatric hospitals it has
found to be out of compliance with
TJC’s program requirements. (This
pertains only to monitoring procedures
when TJC identifies non-compliance. If
noncompliance is identified by a state
survey agency through a validation
survey, the state survey agency monitors
corrections as specified at § 488.9(c)).
++ Assess TJC’s ability to report
deficiencies to the surveyed hospital
and respond to the psychiatric
hospital’s plan of correction in a timely
manner.
++ Establish TJC’s ability to provide
CMS with electronic data and reports
necessary for effective validation and
VerDate Sep<11>2014
20:06 Feb 24, 2023
Jkt 259001
assessment of the organization’s survey
process.
++ Determine the adequacy of TJC’s
staff and other resources.
++ Confirm TJC’s ability to provide
adequate funding for performing
required surveys.
++ Confirm TJC’s policies with
respect to surveys being unannounced.
++ Confirm TJC’s policies and
procedures to avoid conflicts of interest,
including the appearance of conflicts of
interest, involving individuals who
conduct surveys or participate in
accreditation decisions.
++ Obtain TJC’s agreement to provide
CMS with a copy of the most current
accreditation survey together with any
other information related to the survey
as we may require, including corrective
action plans.
IV. Analysis of and Responses to Public
Comments on the Proposed Notice
In accordance with section
1865(a)(3)(A) of the Act, the September
30, 2022 proposed notice also solicited
public comments regarding whether
TJC’s requirements met or exceeded the
Medicare CoPs for psychiatric hospitals.
We received one comment in response
to the proposed notice.
Comment: A commenter expressed
concern about TJC’s ability to protect
disabled patients in facilities that
engage in misconduct and that do not
follow best practices.
Response: We appreciate this
comment and the commenter’s concern
for patient safety. We continue to
prioritize patient safety and our
responsibility for oversight of AOs. As
described in Section III of this notice,
CMS takes various steps when
considering to approve or not approve a
national AO. Each national AO wishing
to be recognized by Medicare as a
national AO must go through a rigorous
process to obtain CMS approval. We
remain steadfast in our commitment to
keeping the public informed of our
evaluation process for national AO
seeking CMS approval.
V. Provisions of the Notice
A. Differences Between TJC’s Standards
and Requirements for Accreditation and
Medicare Conditions of Participation
(CoPs) and Survey Process
Requirements
We compared TJC’s psychiatric
hospital accreditation program
requirements and survey process with
the Medicare CoPs at Part 482 subpart
E, and the survey and certification
process requirements of Parts 488 and
489. Our review and evaluation of TJC’s
psychiatric hospital application, which
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
were conducted as described in section
III of this notice, yielded the following
areas where, as of the date of this notice,
TJC has completed revising its survey
processes in order to demonstrate that it
uses survey processes that are
comparable to state survey agency
processes by:
• Providing additional training to
ensure that TJC psychiatric hospital
surveyors document findings of
noncompliance consistent with the
regulatory requirement in Section
§ 488.5 (a)(4)(iv).
• Providing additional training to
surveyors to ensure any actions taken by
the facility to address the deficiencies
include specific information in the
corrective measures, as provided by
§ 488.5 (a)(4)(vii), and are consistent
with the plan of correction requirements
as described in the State Operations
Manual (SOM), Chapter 2, Section
2728B.
• Revising TJC’s intake/triage process
for all complaint requirements to ensure
comparability with CMS requirements,
§ 488.5(a)(12), and consistent with the
SOM, Chapter 5, Section 5075.2.
• Revising TJC’s complaint policy
regarding offsite investigations and
maximum timeframes to investigate
complaints as described in SOM,
Chapter 5, Sections 5075.5 and 5075.9.
B. Term of Approval
Based on our review and observations
described in section III. and V. of this
notice, we approve TJC as a national AO
for psychiatric hospitals that request
participation in the Medicare program.
The decision announced in this notice
is effective February 25, 2023 through
February 25, 2029. In accordance with
§ 488.5(e)(2)(i), the term of the approval
will not exceed 6 years.
VI. Collection of Information
Requirements
This document does not impose
information collection requirements;
that is, reporting, recordkeeping. or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 3501 et seq.).
The Administrator of the Centers for
Medicare & Medicaid Services (CMS),
Chiquita Brooks-LaSure, having
reviewed and approved this document,
authorizes Lynette Wilson, who is the
Federal Register Liaison, to
electronically sign this document for
purposes of publication in the Federal
Register.
E:\FR\FM\27FEN1.SGM
27FEN1
Federal Register / Vol. 88, No. 38 / Monday, February 27, 2023 / Notices
Dated: February 21, 2023.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare
& Medicaid Services.
[FR Doc. 2023–03925 Filed 2–24–23; 8:45 am]
BILLING CODE P
Electronic Submissions
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2022–N–2782]
Antimicrobial Drugs Advisory
Committee; Notice of Meeting;
Establishment of a Public Docket;
Request for Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice; establishment of a
public docket; request for comments.
ACTION:
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Antimicrobial Drugs
Advisory Committee. The general
function of the committee is to provide
advice and recommendations to FDA on
regulatory issues. The meeting will be
open to the public. FDA is establishing
a docket for public comment on this
document.
SUMMARY:
The meeting will be held
virtually on March 16, 2023, from 9 a.m.
to 5 p.m. Eastern Time.
ADDRESSES: Please note that due to the
impact of the COVID–19 pandemic, all
meeting participants will be joining this
advisory committee meeting via an
online teleconferencing platform.
Answers to commonly asked questions
about FDA advisory committee meetings
may be accessed at: https://
www.fda.gov/AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
FDA is establishing a docket for
public comment on this meeting. The
docket number is FDA–2022–N–2782.
Please note that late, untimely filed
comments will not be considered. The
docket will close on March 15, 2023.
The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of March 15, 2023. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are received
on or before that date.
Comments received on or before
March 9, 2023, will be provided to the
committee. Comments received after
that date will be taken into
consideration by FDA. In the event that
ddrumheller on DSK120RN23PROD with NOTICES
DATES:
VerDate Sep<11>2014
20:06 Feb 24, 2023
Jkt 259001
the meeting is cancelled, FDA will
continue to evaluate any relevant
applications or information, and
consider any comments submitted to the
docket, as appropriate.
You may submit comments as
follows:
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2022–N–2782 for ‘‘Antimicrobial Drugs
Advisory Committee; Notice of Meeting;
Establishment of a Public Docket;
Request for Comments.’’ Received
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
12365
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ FDA
will review this copy, including the
claimed confidential information, in its
consideration of comments. The second
copy, which will have the claimed
confidential information redacted/
blacked out, will be available for public
viewing and posted on https://
www.regulations.gov. Submit both
copies to the Dockets Management Staff.
If you do not wish your name and
contact information be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify the information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
FOR FURTHER INFORMATION CONTACT:
Joyce Frimpong, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–7973, email: AMDAC@fda.hhs.gov,
or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area). A notice in the Federal Register
about last-minute modifications that
impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check FDA’s website at
https://www.fda.gov/
AdvisoryCommittees/default.htm and
E:\FR\FM\27FEN1.SGM
27FEN1
Agencies
[Federal Register Volume 88, Number 38 (Monday, February 27, 2023)]
[Notices]
[Pages 12363-12365]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-03925]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-3430-FN]
Application From the Joint Commission (TJC) for Continued
Approval of its Psychiatric Hospital Accreditation Program
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces our decision to approve the Joint
Commission for continued recognition as a national accrediting
organization for psychiatric hospitals that wish to participate in the
Medicare or Medicaid programs.
DATES: This notice is effective February 25, 2023 through February 25,
2029.
FOR FURTHER INFORMATION CONTACT: Danielle Adams (410) 786-8818, Donald
Howard (410) 786-6764 or Lillian Williams (410) 786-8636.
SUPPLEMENTARY INFORMATION:
I. Background
Under the Medicare program, eligible beneficiaries may receive
covered services from a psychiatric hospital provided certain
requirements are met. Section 1861(f) of the Social Security Act (the
Act) establishes distinct criteria for facilities seeking designation
as a psychiatric hospital. Regulations concerning provider agreements
are at 42 CFR part 489 and those pertaining to activities relating to
the survey and certification of facilities are at 42 CFR part 488. The
regulations at 42 CFR part 482, subpart E, specify the minimum
conditions that a psychiatric hospital must meet to participate in the
Medicare program, the scope of covered services, and the conditions for
Medicare payment for psychiatric hospitals.
Generally, to enter into a provider agreement, a psychiatric
hospital must first be certified by a State Survey Agency as complying
with the conditions or requirements set forth in part 482 subpart E of
our regulations. Thereafter, the psychiatric hospital is subject to
regular surveys by a State Survey Agency to determine whether it
continues to meet these requirements.
Section 1865(a)(1) of the Act provides that, if a provider entity
demonstrates through accreditation by an approved national accrediting
organization (AO) that all applicable Medicare conditions are met or
exceeded, we may treat the provider entity as having met those
conditions; that is, we may ``deem'' the provider entity as having met
the requirements. Accreditation by an AO is voluntary and is not
required for Medicare participation.
If an AO is recognized by the Secretary of the Department of Health
and Human Services (the Secretary) as having standards for
accreditation that meet or exceed Medicare requirements, any provider
entity accredited by the national accrediting body's approved program
may be deemed to meet the Medicare conditions. A national AO applying
for approval of its accreditation program under part 488, subpart A,
must provide Centers for Medicare & Medicaid Services (CMS) with
reasonable assurance that the AO requires the accredited provider
entities to meet requirements that are at least as stringent as the
Medicare conditions. Our regulations concerning the approval of AO are
set forth at Sec. 488.5. The regulations at Sec. 488.5(e)(2)(i)
require AO to reapply for continued approval of its accreditation
program every 6 years or sooner as determined by CMS.
The Joint Commission's current term of approval for their
psychiatric hospital accreditation program expires February 25, 2023.
II. Application Approval Process
Section 1865(a)(3)(A) of the Act provides a statutory timetable to
ensure that our review of applications for CMS approval of an
accreditation program is conducted in a timely manner. The Act provides
no more than 210 days after the date of receipt of a complete
application, including any documentation necessary to make the
determination, for CMS to complete its application review process.
Within 60 days after receiving a complete application, we must publish
a notice in the Federal Register that identifies the national
accrediting body making the request, describes the request, and
provides no less than a 30-day public
[[Page 12364]]
comment period. At the end of the 210-day period, we must publish a
notice in the Federal Register approving or denying the application.
III. Provisions of the Proposed Notice
In the September 30, 2022 Federal Register (87 FR 59435), we
published a proposed notice announcing The Joint Commission (TJC)
request for continued approval of its Medicare psychiatric hospital
accreditation program. In the September 30, 2022 notice, we detailed
our evaluation criteria. Under the authority of Section 1865(a)(2) of
the Act and our regulations at Sec. 488.5, we conducted a review of
TJC's Medicare psychiatric hospital accreditation renewal application
in accordance with the criteria specified by our regulations, which
include, but are not limited to, the following:
An onsite administrative review of TJC's: (1) Corporate
policies; (2) financial and human resources available to accomplish the
proposed surveys; (3) procedures for training, monitoring, and
evaluation of its psychiatric hospital surveyors; (4) ability to
investigate and respond appropriately to complaints against accredited
psychiatric hospitals; and (5) survey review and decision-making
process for accreditation.
The comparison of TJC's Medicare psychiatric hospital
accreditation program standards to our current Medicare hospitals
Conditions of Participation (CoPs) and psychiatric hospital special
conditions.
A documentation review of TJC's psychiatric hospital
survey process to:
++ Determine the composition of the survey team, surveyor
qualifications, and TJC's ability to provide continuing surveyor
training.
++ Compare TJC's processes to those we require of state survey
agencies, including periodic resurvey and the ability to investigate
and respond appropriately to complaints against accredited psychiatric
hospitals.
++ Evaluate TJC's procedures for monitoring psychiatric hospitals
it has found to be out of compliance with TJC's program requirements.
(This pertains only to monitoring procedures when TJC identifies non-
compliance. If noncompliance is identified by a state survey agency
through a validation survey, the state survey agency monitors
corrections as specified at Sec. 488.9(c)).
++ Assess TJC's ability to report deficiencies to the surveyed
hospital and respond to the psychiatric hospital's plan of correction
in a timely manner.
++ Establish TJC's ability to provide CMS with electronic data and
reports necessary for effective validation and assessment of the
organization's survey process.
++ Determine the adequacy of TJC's staff and other resources.
++ Confirm TJC's ability to provide adequate funding for performing
required surveys.
++ Confirm TJC's policies with respect to surveys being
unannounced.
++ Confirm TJC's policies and procedures to avoid conflicts of
interest, including the appearance of conflicts of interest, involving
individuals who conduct surveys or participate in accreditation
decisions.
++ Obtain TJC's agreement to provide CMS with a copy of the most
current accreditation survey together with any other information
related to the survey as we may require, including corrective action
plans.
IV. Analysis of and Responses to Public Comments on the Proposed Notice
In accordance with section 1865(a)(3)(A) of the Act, the September
30, 2022 proposed notice also solicited public comments regarding
whether TJC's requirements met or exceeded the Medicare CoPs for
psychiatric hospitals. We received one comment in response to the
proposed notice.
Comment: A commenter expressed concern about TJC's ability to
protect disabled patients in facilities that engage in misconduct and
that do not follow best practices.
Response: We appreciate this comment and the commenter's concern
for patient safety. We continue to prioritize patient safety and our
responsibility for oversight of AOs. As described in Section III of
this notice, CMS takes various steps when considering to approve or not
approve a national AO. Each national AO wishing to be recognized by
Medicare as a national AO must go through a rigorous process to obtain
CMS approval. We remain steadfast in our commitment to keeping the
public informed of our evaluation process for national AO seeking CMS
approval.
V. Provisions of the Notice
A. Differences Between TJC's Standards and Requirements for
Accreditation and Medicare Conditions of Participation (CoPs) and
Survey Process Requirements
We compared TJC's psychiatric hospital accreditation program
requirements and survey process with the Medicare CoPs at Part 482
subpart E, and the survey and certification process requirements of
Parts 488 and 489. Our review and evaluation of TJC's psychiatric
hospital application, which were conducted as described in section III
of this notice, yielded the following areas where, as of the date of
this notice, TJC has completed revising its survey processes in order
to demonstrate that it uses survey processes that are comparable to
state survey agency processes by:
Providing additional training to ensure that TJC
psychiatric hospital surveyors document findings of noncompliance
consistent with the regulatory requirement in Section Sec. 488.5
(a)(4)(iv).
Providing additional training to surveyors to ensure any
actions taken by the facility to address the deficiencies include
specific information in the corrective measures, as provided by Sec.
488.5 (a)(4)(vii), and are consistent with the plan of correction
requirements as described in the State Operations Manual (SOM), Chapter
2, Section 2728B.
Revising TJC's intake/triage process for all complaint
requirements to ensure comparability with CMS requirements, Sec.
488.5(a)(12), and consistent with the SOM, Chapter 5, Section 5075.2.
Revising TJC's complaint policy regarding offsite
investigations and maximum timeframes to investigate complaints as
described in SOM, Chapter 5, Sections 5075.5 and 5075.9.
B. Term of Approval
Based on our review and observations described in section III. and
V. of this notice, we approve TJC as a national AO for psychiatric
hospitals that request participation in the Medicare program. The
decision announced in this notice is effective February 25, 2023
through February 25, 2029. In accordance with Sec. 488.5(e)(2)(i), the
term of the approval will not exceed 6 years.
VI. Collection of Information Requirements
This document does not impose information collection requirements;
that is, reporting, recordkeeping. or third-party disclosure
requirements. Consequently, there is no need for review by the Office
of Management and Budget under the authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501 et seq.).
The Administrator of the Centers for Medicare & Medicaid Services
(CMS), Chiquita Brooks-LaSure, having reviewed and approved this
document, authorizes Lynette Wilson, who is the Federal Register
Liaison, to electronically sign this document for purposes of
publication in the Federal Register.
[[Page 12365]]
Dated: February 21, 2023.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2023-03925 Filed 2-24-23; 8:45 am]
BILLING CODE P